ABSTRACT
Drug delivery to the brain is restrained by the blood-brain barrier (BBB), a physical and biochemical barrier
separating the brain from the circulatory system. Small molecule drugs move across the BBB mainly via
transcellular passive diffusion and transporter-mediated active transport. The BBB in brain tumors is disrupted
to varying extent, leading to large intra- and inter-individual variability in drug tumor exposure. Mechanistic
understanding and prediction of heterogeneous drug penetration across the intact BBB and disrupted blood-
brain tumor barrier (BBTB) is of paramount importance to rational drug development and treatment for brain
cancer. Given the fact that the rate and extent of drug penetration across the BBB is determined by both
biological system characteristics and drug properties, prediction of human BBB/BBTB permeability from
preclinical in vitro or animal models is complicated by biological system differences. Hence, the development of
innovative approaches is imperative. The in vitro-in vivo extrapolation-physiologically based pharmacokinetic
(IVIVE-PBPK) model offers a unique platform that allows simultaneous incorporation of drug- and system-
specific parameters into a PK model and enables a priori prediction of individual in vivo kinetic processes based
on mechanistic scaling of in vitro data (e.g., in vitro enzyme and transporter kinetics). The overall goal of this
project is to develop a mechanism-based PBPK model platform for predicting heterogeneous drug penetration
into the human brain and brain tumors. We will employ an integrated translational research approach to achieve
this goal, which leverages in vitro pharmacology studies, PK modeling, and clinical trials. Three drugs (AZD1775,
ceritinib, and ribociclib) will be used for initial model development and verification, and additional 3 drugs
(everolimus, abemaciclib, and LY3214996) will be used for further model validation. These drugs have been or
is being evaluated in glioblastoma patients in our clinical trial program. Observed clinical plasma and brain tumor
PK data are available for model development and validation. As the first step towards resolving the gap of our
knowledge on BBB transporter abundances, which is essential to establishing IVIVE scaling factors for predicting
transporter-mediated active clearance at the human BBB and BBTB, Aim 1 is to determine transporter protein
abundances in isolated microvessels of non-cancerous cortex as well as contrast-enhancing and non-enhancing
glioblastoma specimens. Aim 2 is to determine drug-specific parameters for metabolism, passive transcellular
permeability, and interaction with efflux and uptake drug transporters. Aim 3 is to develop and validate a novel
7-compartment permeability-limited brain (7Brain) PBPK model, which accounts for brain and tumor regional
physiological differences in blood perfusion, pH, BBB/BBTB integrity, and transporter expression. The 7Brain
PBPK model is the first-of-its kind, mechanism-based model platform for the prediction of heterogeneous drug
penetration across the human BBB and BBTB. It promises to be a valuable tool to assist the development and
design of improved drugs and dosing regimens for more effective treatment of brain cancer.